SAN DIEGO , July 29, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent

Results from proof-of-concept study are expected in September 2021 . SAN DIEGO , July 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that

Event will feature Dr. Daniel Culver , Director of the Interstitial Lung Disease Program at the Cleveland Clinic . Conference call and webcast scheduled for Tuesday June 29 th at 5:00pm ET / 2:00pm PT . SAN DIEGO , June 23, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

  Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2. aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways which are implicated in immune-mediated diseases. SAN DIEGO , June 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

SAN DIEGO , May 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Sara Zaknoen , M.D., to the company’s Board of Directors.

Findings advance understanding of mechanistic impact of blocking NRP2/VEGF signaling axis with ATYR2810 on aggressive tumor cells SAN DIEGO , May 19, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines

Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter. Preclinical data for IND candidate ATYR2810 showed anti-tumor effects in models of TNBC and NSCLC. Bispecific antibody project with subsidiary Pangu BioPharma achieved milestones for first of

Two-year grant awarded by the Hong Kong Government’s Innovation and Technology Commission is funding the development of new bispecific antibodies targeting NRP2 SAN DIEGO , May 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and

SAN DIEGO , May 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the promotion of Leslie Nangle , Ph.D., to Vice President, Research. Dr.

Management to host conference call and webcast on May 13th at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , May 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today